Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0003873 (rheumatoid arthritis)
 53,068 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fenoprofen1 (dl-2-[3-phenoxyphenyl]propionic acid) is a new non-steroidal anti-inflammatory, antipyretic, analgesic agent advocated for use in rheumatoid arthritis, degenerative joint disease, ankylosing spondylitis and gout. Published data suggest that in rheumatoid arthritis, fenoprofen 2.4 g daily is comparable in effectiveness with moderate doses of aspirin (3.6 to 4 g daily), but generally causes fewer and milder side-effects at the dosages used. In published comparisons with other non-steroidal anti-inflammatory agents of the same chemical group, it is closely comparable with naproxen in effectiveness but tends to cause more minor side-effects than naproxen. However, as no one of the non-steroidal anti-inflammatory agents is the most suitable drug for all patients requiring such therapy, fenoprofen should be considered along with the other drugs of its type in the initial treatment of the arthritic patient. Fenoprofen has compared favourably with phenylbutazone in osteoarthrosis of the hips and with aspirin in osteoarthrosis of the shoulders, hips, knees and spine. Its exact place in the management of gout and ankylosing spondylitis remains to be determined.
 ...
PMID:Fenoprofen: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. 32 48

In 88.9% of a group of 18 patients with rheumatoid arthritis participating in an open-label study with fenoprofen calcium (Nalfon), there was observed a mean titre decrease in level of rheumatoid factor as compared to baseline levels. In follow-up, three months to one year later, a uniform titre increase above the mean level of the study period had occurred. In all cases the titre returned to baseline levels or higher.
 ...
PMID:The effect of fenoprofen calcium (Nalfon) on levels of rheumatoid factor in patients with rheumatoid arthritis. 33 91

Ninety patients with rheumatoid arthritis completed a double-blind crossover trial comparing fenoprofen, ibuprofen, ketoprofen, and naproxen. Fenoprofen and naproxen were slightly more effective than the other two drugs but there were striking individual variations in response. Groups of patients could be identified who preferred each of the four drugs. The commonest side effects were those related to the upper gastrointestinal tract; these showed individual variation and seldom occurred with more than one or two of the drugs. Side effects were least common with ibuprofen and naproxen. Since naproxen combined greater effectiveness with a lower incidence of side effects it must be regarded as the first choice among these drugs. It may be necessary to try several drugs before finding the right one for a particular patient.
 ...
PMID:Four new anti-inflammatory drugs: responses and variations. 77 99

Fenoprofen calcium (FC) was compared to aspirin (ASA) in 20 patients with rheumatoid arthritis in a double-blind parallel study. The average daily dose was 2.0 gm of FC, or 3.6 gm of ASA. Most patients on FC therapy responded similarly to those receiving ASA, but FC was slightly better in reducing morning stiffness, walking time, fatigue severity, and activity index. More FC treated than ASA treated patients became worse when placebo was substituted after one year of therapy, with a greater increase in the number and severity of painful and swollen joints, in addition to the above mentioned parameters. This suggests a greater suppression of the inflammatory process during FC therapy. FC was well tolerated and had a greater antirheumatic effect than aspirin. Both drugs were superior to placebo.
 ...
PMID:Fenoprofen calcium therapy in rheumatoid arthritis. 78 Dec 26

Thirty patients with active definite or classic rheumatoid arthritis (RA), participated in a double-blind crossover study comparing fenoprofen calcium with placebo. All patients were receiving maintenance gold therapy. Fenoprofen was administered in doses ranging from 200 to 800 mg every six hours. The median daily dose was 1.8 gm. During this 16-week trial, most parameters of efficacy showed fenoprofen to be significantly more effective than placebo. Adverse reactions, which were minimal, suggest that fenoprofen will be useful in the management of patients with RA, particularly in those with gastrointestinal intolerance to the usually employed drugs. The longterm effectiveness in RA, and the side effects associated with chronic administration remain to be assessed.
 ...
PMID:Fenoprofen in patients with rheumatoid arthritis receiving maintenance gold therapy. 78 Dec 28

Twenty-one patients with active rheumatoid arthritis on maintenance corticosteroids were studied during a double-blind, crossover trial with fenoprofen. Fenoprofen showed significantly greater effect than did placebo on several subjective and objective measurements. In addition, patients were able to reduce their dose of corticosteroid to a level significantly lower than that during placebo periods. Though three patients dropped out of the study with gastrointestinal complaints while on fenoprofen, only one of these was believed to be drug-related. No serious adverse effects were encountered.
 ...
PMID:Fenoprofen calcium in steroid treated rheumatoid arthritis: efficacy, safety, and steroid-sparing effect. 78 Dec 29

Fenoprofen, a new antirheumatic agent, was evaluated in 45 patients with rheumatoid arthritis in an open study design to simulate the conditions under which the drug will be used. No control agents were used. The effectiveness of fenoprofen was demonstrated by the per cent of patients who improved during fenoprofen therapy. Duration of therapy varied from one to 629 days. Pain was the first parameter to respond, followed by an anti-inflammatory effect, which was observed after four to six weeks of therapy. Side effects consisted mainly of minor gastro-intestinal symptoms.
 ...
PMID:Longterm fenoprofen therapy in patients with rheumatoid arthritis. 78 Dec 30

Fenoprofen calcium was compared with acetylsalicylic acid in the treatment of 27 patients with definite or classic rheumatoid arthritis, over a period of one year. Both drugs appeared efficacious, with a slight edge to fenoprofen in the doses employed. Fewer side effects were noted with fenoprofen. Effectiveness continued undiminished throughout the year, and mean values of most parameters continued to improve in both groups over the entire period. Three problems which influence extrapolation of results from this and similar studies to the general setting are discussed. (1) Individual patients show great variation from the mean and from one observation point to another. Thus, expectations developed from mean values will seldom be accurate in a particular patient. (2) The relative doses chosen for two drugs in the clinical trial can profoundly influence both efficacy and toxicity. The qualification "at the doses employed" is seldom emphasized in clinical reports. (3) Patient compliance in the general clinical setting is importantly different from that in a clinical trial, and this potential problem must be assessed by the physician choosing an appropriate medication for a particular patient.
 ...
PMID:Some problems in the interpretation of clinical trials: longterm parallel study of fenoprofen in rheumatoid arthritis. 78 Dec 32

Fenoprofen, a compound with analgesic, anti-inflammatory, and antipyretic properties in animals, has been compared with placebo in a double-blind cross-over trial in 60 patients with rheumatoid arthritis. There was a statistically highly significant reduction in pain, duration of morning stiffness, analgesic requirements, and articular index, with increase in grip strength. There was no significant reduction in joint size or temperature. In a subsequent double-blind group-comparative study fenoprofen proved to be as effective as aspirin in relieving the symptoms of rheumatoid arthritis, with strikingly fewer side effects. Almost half of the patients taking aspirin were unable to tolerate the drug in adequate dosage for six months. The remainder were able to take on average only 4 g daily, and at this dose almost half still complained of tinnitus and deafness.Fenoprofen is likely to be useful for patients who cannot tolerate aspirin and other more toxic anti-inflammatory drugs or whose disease is not of sufficient severity to justify their use.
 ...
PMID:Treatment of rheumatoid arthritis with fenoprofen: comparison with aspirin. 459 Jun 69